Network for myelofibrosis and related blood cancers
Official title: Myeloproliferative Neoplasms-Research Consortium
Funded at Icahn School of Medicine at Mount Sinai · NIH-11094798 · Data updated 2026-11-12
Doctors at multiple hospitals are testing new treatments to help people with myelofibrosis and related blood cancers live longer and feel better.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2006 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $3,957,858 |
| NIH project number | 5P01CA108671-17 |
| Project ID | NIH-11094798 on NIH RePORTER |
Who could benefit from this research
✓Could help
People diagnosed with myelofibrosis or other myeloproliferative neoplasms, particularly those who are not candidates for stem cell transplant or who have stopped JAK2 inhibitor therapy, are the intended candidates.
✕Less likely to help
People without myeloproliferative neoplasms or those with unrelated medical conditions would not be eligible and are unlikely to benefit directly.
What this research studies
This consortium brings together laboratory and clinical teams at 13 centers to develop and run new treatment trials for myelofibrosis, polycythemia vera, and essential thrombocythemia. The focus is on therapies that go beyond first-generation JAK2 drugs by targeting the disease at the stem-cell level and seeking disease-modifying effects. Promising approaches move from lab studies into coordinated multi-center clinical trials so patients can access new options more quickly. Participants may be asked to provide blood or tissue samples and to attend clinic visits for treatment and follow-up.
Why it matters
Potential benefit: Could produce better therapies that reduce symptoms, slow or reverse disease progression, and improve survival for patients with myelofibrosis and related disorders.
How similar studies have gone: First-generation JAK2 inhibitor trials have improved symptoms but not cured disease, and this consortium builds on that work to test newer, potentially disease-modifying strategies.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Hoffman, Ronald — Icahn School of Medicine at Mount Sinai
- Study coordinator: Hoffman, Ronald
Related research
Other NIH-funded projects on the same topics.
-
Biomarker clues to catch pancreatic cancer early in cysts
A study from UC San Diego is testing blood and cyst-fluid markers to help tell high-risk pancreatic cysts from low-risk ones so that people with pancreatic cysts can get the right care sooner.
-
Myeloproliferative Neoplasm Research Consortium
A large research collaboration across multiple centers aims to improve survival for patients with myelofibrosis and related myeloproliferative neoplasms through coordinated laboratory, translational, and clinical work.
-
Understanding how different CALR mutations drive certain blood cancers
This grant explores how two CALR mutation types cause myeloproliferative neoplasms and could lead to better treatments for people with these blood cancers.
-
Cell Competition in Myeloproliferative Neoplasms
This NIH grant explores how healthy and mutant blood stem cells interact in certain blood cancers to understand why some patients progress and how future therapies might help.
-
Targeting ERK’s brake pedals to slow cancer progression
Aims to block the parts of ERK signaling that speed up cancer progression, by guiding drugs to the substrate-binding domains that act like accelerator pedals in myeloproliferative neoplasms and related cancers.
-
Biomarker work to predict pancreatic IPMN cancer risk
A Duke University researcher is testing biomarkers to tell which pancreatic IPMN cysts are likely to become invasive cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.